These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8059228)

  • 21. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.
    Valentin S; Nordfang O; Bregengård C; Wildgoose P
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):713-20. PubMed ID: 8292720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes.
    Golino P; Ravera A; Ragni M; Cirillo P; Piro O; Chiariello M
    Circulation; 2003 Dec; 108(23):2864-9. PubMed ID: 14656922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
    Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases].
    Saito M; Morishita E; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Matsuda T
    Rinsho Ketsueki; 1996 Sep; 37(9):794-8. PubMed ID: 8914465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein.
    Horie S; Hiraishi S; Hamuro T; Kamikubo Y; Matsuda J
    Thromb Haemost; 2002 Jan; 87(1):80-5. PubMed ID: 11848461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells.
    Giraux JL; Tapon-Bretaudière J; Matou S; Fischer AM
    Thromb Haemost; 1998 Oct; 80(4):692-5. PubMed ID: 9798992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle.
    Lindahl AK
    Cardiovasc Res; 1997 Feb; 33(2):286-91. PubMed ID: 9138864
    [No Abstract]   [Full Text] [Related]  

  • 28. Anticoagulant actions of tissue factor pathway inhibitor on tissue-factor-dependent plasma coagulation.
    Ofosu FA
    Semin Thromb Hemost; 1995; 21(2):240-4. PubMed ID: 7660146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
    Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T
    Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration.
    Cella G; Cipriani A; Tommasini A; Rampin E; Sbarai A; Rocconi R; Mazzaro G; Luzzatto G
    Semin Thromb Hemost; 1997; 23(1):45-9. PubMed ID: 9156410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue factor pathway inhibitor.
    Broze GJ
    Thromb Haemost; 1995 Jul; 74(1):90-3. PubMed ID: 8578532
    [No Abstract]   [Full Text] [Related]  

  • 33. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
    Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated release of the tissue factor pathway inhibitor.
    Ariëns RA; Faioni EM; Mannucci PM
    Thromb Haemost; 1994 Aug; 72(2):327-8. PubMed ID: 7831675
    [No Abstract]   [Full Text] [Related]  

  • 35. Tissue factor pathway inhibitor; its structure, function and clinical significance.
    Kato H
    Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
    Hansen JB; Sandset PM; Huseby KR; Huseby NE; Nordøy A
    Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin.
    Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN
    Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins.
    Jeske W; Lormeau JC; Callas D; Iqbal O; Hoppensteadt D; Fareed J
    Semin Thromb Hemost; 1995; 21(2):193-200. PubMed ID: 7660142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue factor pathway inhibitor and heparin.
    Abildgaard U
    Adv Exp Med Biol; 1992; 313():199-204. PubMed ID: 1442262
    [No Abstract]   [Full Text] [Related]  

  • 40. The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis.
    Levi M
    Crit Care Med; 2002 Aug; 30(8):1914-5. PubMed ID: 12163821
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.